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Abstract
Background: Comorbidity is common and has a substantial negative impact on the prognosis of patients with
acute myocardial infarction (AMI). Whilst receipt of guideline-indicated treatment for AMI is associated with
improved prognosis, the extent to which comorbidities influence treatment provision its efficacy is unknown.
Therefore, we investigated the association between treatment provision for AMI and survival for seven common
comorbidities.
Methods: We used data of 693,388 AMI patients recorded in the Myocardial Ischaemia National Audit Project
(MINAP), 2003–2013. We investigated the association between comorbidities and receipt of optimal care for AMI
(receipt of all eligible guideline-indicated treatments), and the effect of receipt of optimal care for comorbid AMI
patients on long-term survival using flexible parametric survival models.
Results: A total of 412,809 [59.5%] patients with AMI had at least one comorbidity, including hypertension (302,388
[48.7%]), diabetes (122,228 [19.4%]), chronic obstructive pulmonary disease (COPD, 89,221 [14.9%]), cerebrovascular
disease (51,883 [8.6%]), chronic heart failure (33,813 [5.6%]), chronic renal failure (31,029 [5.0%]) and peripheral
vascular disease (27,627 [4.6%]).
Receipt of optimal care was associated with greatest survival benefit for patients without comorbidities (HR 0.53,
95% CI 0.51–0.56) followed by patients with hypertension (HR 0.60, 95% CI 0.58–0.62), diabetes (HR 0.83, 95% CI
0.80–0.87), peripheral vascular disease (HR 0.85, 95% CI 0.79–0.91), renal failure (HR 0.89, 95% CI 0.84–0.94) and
COPD (HR 0.90, 95% CI 0.87–0.94). For patients with heart failure and cerebrovascular disease, optimal care for AMI
was not associated with improved survival.
Conclusions: Overall, guideline-indicated care was associated with improved long-term survival. However, this was
not the case in AMI patients with concomitant heart failure or cerebrovascular disease. There is therefore a need for
novel treatments to improve outcomes for AMI patients with pre-existing heart failure or cerebrovascular disease.
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Background
Comorbidity is common and has a substantial negative
impact on the prognosis of patients with acute myocardial
infarction (AMI) [1–3]. Receipt of guideline-indicated
treatments for AMI is associated with improved survival
[4–6], reduced morbidity [6] and lower subsequent health-
care expenditure [7]. However, there is little information
about the impact of comorbidities on the receipt of treat-
ment for AMI and, in particular, the impact of these treat-
ments on prognosis for a range of comorbidities. Over
100,000 people in the United Kingdom (UK) were admit-
ted to hospital with AMI in 2017/2018 [8], and of these,
59.5% have comorbidities [1]. It is therefore necessary to
identify comorbidity states where receipt of treatment is
suboptimal, or where AMI treatment has little impact on
prognosis in order to guide research into novel therapies,
thereby optimising patient-centred care delivery.
Whilst there is good evidence to suggest that comorbidity
adversely influences treatment pathways for a number of
specific diseases including diabetes, cancer and chronic ob-
structive pulmonary disease (COPD) [3, 9–12], there is a
paucity of information about the impact of comorbidity on
treatment delivery and treatment efficacy for AMI. For ex-
ample, it has been shown that patients with cancer who
present with AMI are less likely to receive percutaneous cor-
onary intervention (PCI), P2Y12 inhibitors and statin therapy
[13]; those with COPD and AMI are less likely to receive
beta-blockers [14]; and those with mental health disorders
and AMI are less likely to receive reperfusion therapy [15].
Patients with AMI and diabetes have reduced survival at 30
days and 1 year [16–18]. Notably, the evidence to date is lim-
ited to studies of the impact of a single comorbidity on the
treatment for AMI [13–15], and based on either small-scale
single centre data with long-term follow-up [14] or large-
scale multicentre data with outcomes limited to in-hospital
or short-term mortality [13, 15]. Moreover, to our know-
ledge, there is no evidence to date concerning the efficacy of
AMI treatments on clinical outcomes for patients with AMI
and comorbidity.
The UK is one of only two countries worldwide that
has a continuous acute coronary syndrome clinical regis-
try that includes all hospitals in its nationwide health
service and has detailed information about patient and
treatment characteristics—the Myocardial Ischaemia Na-
tional Audit Project (MINAP). MINAP provides a
unique opportunity to undertake high resolution
phenotype-specific interrogation of comorbidity, treat-
ment pathways and long-term survival for patients with
AMI in a nationwide cohort. In the absence of previous
robust evidence, our objectives in this study were to as-
sess both the effect of comorbidity states on receipt of
guideline-indicated AMI care, and the impact of receipt
of care on long-term survival outcomes in the presence
of comorbidity.
Methods
Study design and participants
Data were obtained from MINAP, a comprehensive na-
tional clinical registry of patients hospitalised with AMI
which includes 130 data fields collected during AMI pa-
tients’ treatment course from the first contact, throughout
hospitalisation, to discharge and rehabilitation [19, 20].
Submission of data to MINAP is mandated by the Depart-
ment of Health for all hospitals in England and Wales.
Data are collected prospectively at each hospital, electron-
ically encrypted and transferred online to a central data-
base. Data entry is subject to routine error checking and
an annual data validation exercise. Mortality data are ob-
tained through linkage with the Office for National Statis-
tics death records. Further details of MINAP have been
published elsewhere [19–22].
The analytical cohort included 693,388 patients aged 18
years and over who were admitted to hospital with AMI
between January 1, 2003, and June 30, 2013 (Fig. 1) [1].
The National Institute for Cardiovascular Outcomes Re-
search (NICOR) which includes the MINAP database (ref:
NIGB: ECC 1-06 (d)/2011) has support under section 251
of the National Health Service Act 2006 to use patient in-
formation for medical research without informed consent.
Ethical approval for this study was not required under
current National Health Service (NHS) research govern-
ance arrangements for the secondary use of anonymised
patient data collected during the course of normal care.
In order to ensure accuracy of AMI treatment effects on
patients, only index admission data was used in this study.
Patients with a history of any of the following conditions
were considered to have comorbidity: diabetes mellitus,
COPD or asthma, hypertension, chronic heart failure,
chronic renal failure, cerebrovascular disease and peripheral
vascular disease. Guideline-indicated treatment was deter-
mined according to previously published work that mapped
MINAP variables to the relevant international guidelines
for the management of AMI [22]. This included pharmaco-
logical therapies (aspirin prior to, and at, admission; β-
blockers, statins, angiotensin-converting enzyme inhibitors
[ACEi] or angiotensin receptor blockers [ARB], P2Y12 in-
hibitors and aldosterone antagonists at discharge), non-
invasive treatment (electrocardiogram, echocardiography,
cardiac rehabilitation, smoking cessation advice, dietary ad-
vice) and invasive treatment (early invasive coronary proce-
dures (reperfusion within 12 h for ST-elevation myocardial
infarction (STEMI)), and an invasive coronary strategy (cor-
onary angiography, PCI or coronary artery bypass graft
(CABG) surgery) for non-STEMI (NSTEMI)) [23]. Treat-
ment receipt was objectively recorded, with the exception
of cardiac rehabilitation—which is accessed through a post-
discharge referral, and is therefore a proxy measure for its
receipt. Patients were classified as ineligible for a treatment
if it was recorded within MINAP as contraindicated, not
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indicated or not applicable; if the patient declined treat-
ment; or if the patient was hospitalised prior to the year in
which the guideline treatment recommendation was pub-
lished. Full eligibility criteria for therapy can be found in
Additional file 1: Table S1. In addition, the following
patient-level demographic data (sex, index of multiple
deprivation (IMD) score—a marker for socioeconomic sta-
tus), Global Registry of Acute Coronary Events (GRACE)
risk score (including age, cardiac arrest, ST-segment devi-
ation, elevated enzyme levels, systolic blood pressure, heart
rate, loop diuretic [substituted for Killip class] and creatin-
ine) and clinical characteristics (total cholesterol, discharge
diagnosis (STEMI, NSTEMI), previous CABG surgery, pre-
vious PCI) were extracted from MINAP.
Patient and public involvement
Patient and public involvement (PPI) representatives
were consulted at the research design stage by providing
insights into the burden of comorbidity and treatments
from a patients’ perspective. They noted it was import-
ant for care provision to be monitored more closely for
people with long-term health conditions, and were keen
to see the outputs of proposed research. It was difficult
to involve patients in other areas of the study due to
data protection restrictions and the very technical
methods required to analyse this large-scale health data.
However, the database used in the study is managed by
NICOR who work closely with PPI representatives and
were commended for their excellence in PPI engagement
in clinical audits by the Healthcare Quality Improvement
Partnership (HQIP). PPI representatives were keen to
stress that they feel information leaflets on the wards
were the best way to disseminate our research findings
directly to the relevant patient groups, and they will co-
design such a leaflet containing lay summaries for dis-
semination to their peers.
Statistical analysis
Treatment eligibility and receipt of each of the 13
guideline-indicated therapies as outlined above were cal-
culated based on respective European Society of Cardi-
ology guidelines for management of AMI, and mapped
Fig. 1 Derivation of the analytical cohort
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to MINAP data. A cumulative treatment score of treat-
ments received out of total treatments for which the pa-
tient was eligible was derived [21]. Optimal care was
defined as receipt of all treatments for which an individ-
ual was eligible (maximum score 13). Baseline character-
istics were described according to each comorbidity
using numbers and percentages for categorical data,
means and standard deviation for normally distributed
data and median and interquartile ranges for non-
normally distributed data. A cumulative treatment score
was calculated for patients with no comorbidity, for each
comorbidity individually and for any comorbidity. The
proportion with a receipt rate of at least 80% of all eli-
gible treatments was also reported [24].
Multiple imputation by chained equations was used to
create ten imputations each, with 20 iterations based on
a comprehensive set of all analyses variables and auxil-
iary variables in order to minimise potential bias due to
missing data [1]. All models presented in the main body
of the paper represent pooled estimates with accom-
panying 95% confidence intervals according to Rubin’s
rules across ten imputed datasets [25]. Full imputation
model specification and a sensitivity analysis comparing
results to a complete case analysis have been reported in
Additional file 1: TableS2, S8-S11.
A series of logistic regression models were fitted to de-
termine the association between the presence of each
comorbidity on the receipt of optimal care for AMI (an
all-or-none treatment approach). To validate this all-or-
none approach, Poisson regression models were per-
formed using the cumulative treatment score. For each
model, we present unadjusted results alongside those ad-
justed for patient demographics (age, sex and IMD
score) and a final fully adjusted model including GRACE
risk score, year of diagnosis, smoking status, IMD score
and each of the seven comorbidities.
To determine the combined association of comorbidi-
ties and treatment on survival, a series of Royston-
Parmar flexible parametric survival models were fitted
using interaction terms which included four possible ex-
posures: those without a pre-specified comorbidity who
received suboptimal care, those with the comorbidity
who received suboptimal care, those without comorbid-
ity who received optimal care and patients with comor-
bidity who received optimal care. For each survival
model, we present unadjusted results alongside those ad-
justed for patient demographics (age, sex and IMD
score) and a final fully adjusted model including GRACE
risk score, year of diagnosis, smoking status, IMD score
and each of the seven comorbidities. Royston-Parmar
flexible parametric survival models were chosen in
favour of standard Cox proportional hazards models for
which the assumptions were not met. Selection of the
scale (hazard, odds, normal or theta) and the complexity
(number of degrees of freedom) of the models were in-
formed by minimising Akaike and Bayesian information
criteria.
Sensitivity analyses were conducted to determine the
combined association of each respective comorbidity
and treatment on survival for those patients who had a
single comorbidity compared with those in whom no co-
morbidities were recorded. All tests were 2-sided, and
statistical significance was considered as P < 0.05. Statis-
tical analyses were performed in Stata IC version 14.2
and R version 3.4.3.
Results
There were 693,388 patients with AMI (274,220 [39.6%]
STEMI; 419,168 [60.5%] NSTEMI) with no comorbidi-
ties recorded in 280,579 (40.5%) and at least one comor-
bidity in the remainder (412,809 [59.5%]) (Fig. 1). Of this
analytical cohort (median age 70.7 [IQR 59.4 to 80.1]
years, 238,569 [34.5%] women), the median survival time
was 2.25 years (IQR 0.88 to 4.00); 1,872,468 total person-
years follow-up. The most prevalent comorbidity was
hypertension (302,388 [43.6%]), followed by diabetes
mellitus (122,228 [17.6%]), COPD or asthma (89,221
[12.9%]), cerebrovascular disease (51,883 [7.5%]), chronic
heart failure (33,813 [4.9%]), renal failure (31,029 [4.5%])
and peripheral vascular disease (27,627 [4.0%]) (Table 1).
Those without comorbidities were younger (median age
65.2 years [IQR 54.8 to 76.9]) of whom most were men
(198,279 [70.9%]) compared to patients with comorbidi-
ties (Table 1). Across all comorbidities, more than two
thirds of AMIs were NSTEMI, whereas amongst those
without comorbidities, only half were NSTEMI (141,185
[50.3%]) (Table 1).
Receipt of care
The recorded use of ECG on admission was high across
all comorbidities (≥ 93%), whilst the recorded provision of
smoking cessation advice was consistently low (≤ 20%)
(Table 2). The use of aspirin in the acute phase and some
pharmacotherapies at time of hospital discharge (aspirin,
ACEi/ARB and statins) was consistently high (> 70%); in
contrast, the use of P2Y12 inhibitors and aldosterone an-
tagonists at discharge was low across all comorbidities (<
45%). The use of an invasive coronary strategy was lower
for those with comorbidities compared to those without,
in particular for those with chronic heart failure (8864
[28.7%]), chronic renal failure (10,158 [36.2%]) and cere-
brovascular disease (18,190 [62.5%]) compared to those
without comorbidities (157,354 [57.7%]) (Table 2). AMI
patients with only one comorbidity had similar rates of
treatment receipt (Additional file 1: Table S3). Overall, pa-
tients with chronic heart failure had the lowest cumulative
treatment score, receiving on average 60.0% of eligible
treatments (IQR 42.9 to 80.0%) (Table 2). Patients with
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Table 2 Proportion of patients who received guideline-indicated treatment for which they were eligible according to comorbidity
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17.4 (24,966) 8.3 (1248) 11.8
(1461)








































































15.1 (45,657) 8.6 (2916) 13.2
(4101)






COPD chronic obstructive pulmonary disease, ACE inhibitors angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, ECG electrocardiogram,
N/A not applicable as do not meet eligibility criteria; full eligibility criteria in appendices; smoking cessation advice given to those with smoking history; acute
aspirin includes only those with direct admission who were not already on aspirin or contraindicated; early invasive coronary procedures include primary PCI or
thrombolysis within 12 h for STEMI and coronary angiography or PCI within 72 h for NSTEMI patients; patients were classified as ineligible if a treatment was listed
as contraindicated, not indicated, or not applicable; if the patient declined treatment as recorded in MINAP; or if the patient was hospitalised prior to the
publication year of treatment recommendation in the guidelines
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hypertension (34.6%) and diabetes mellitus (34.0%) had
the highest proportion with cumulative treatment score of
80% or more, in contrast to patients with heart failure of
whom only 25.2% had a cumulative treatment score of
80% or more (Fig. 2).
The presence of each comorbidity, with the exception
of hypertension, renal failure and peripheral vascular dis-
ease, was associated with a reduced chance of receiving
optimal care. The effect was most pronounced in those
with chronic heart failure (OR 0.63, 95% CI 0.60 to
0.65), followed by cerebrovascular disease (OR 0.86, 95%
CI 0.84 to 0.89) and diabetes mellitus (OR 0.89, 95% CI
0.88 to 0.91) (Fig. 3; Additional file 1: Table S4). Simi-
larly, the presence of each comorbidity (with the excep-
tion of hypertension, chronic renal failure and peripheral
vascular disease) was associated with an increased risk of
receiving fewer guideline-recommended treatments. The
greatest discrepancy was seen in patients with chronic
heart failure (incidence risk ratio 0.94, 95% CI 0.94 to
0.95) (Additional file 1: Table S4). In patients with only
hypertension (OR 0.98, 95% CI 0.96–1.00) or only per-
ipheral vascular disease (OR 0.96, 95% CI 0.87–1.07),
there was no significant difference in the receipt of opti-
mal care compared to those with no comorbidities (Add-
itional file 1: Table S5). Similar results were observed in
the complete case analysis (Additional file 1: Table S6),
in which optimal care receipt was similar in patients
with peripheral vascular disease to those with no comor-
bidities (OR 1.03, 95% CI 0.99–1.08), whereas all other
comorbidities were associated with a differential receipt
of treatment (Additional file 1: Table S7).
Receipt of care and long-term survival
Over the 8.5-year follow-up period, the receipt of optimal
care in patients without comorbidities was associated with
a 47% reduced risk of death (adjusted HR 0.53, 95% CI 0.51
to 0.56) compared with a 9% reduced risk of death (ad-
justed HR 0.91, 95% CI 0.88 to 0.93) for patients who
received optimal care and had at least one comorbidity
(Fig. 4). Specifically, in patients with AMI who also had
hypertension, diabetes mellitus, peripheral vascular disease,
chronic renal failure and COPD or asthma, receipt of opti-
mal AMI care was associated with a 40%, 17%, 15%, 11%
and 10% relative reduced risk of death, respectively. How-
ever, for those with chronic heart failure and cerebrovascu-
lar disease and in patients with at least two comorbidities,
the receipt of optimal AMI care was not associated with a
significant change in survival (HR 1.02, 95% CI 0.96 to 1.09;
HR 0.97, 95% CI 0.92 to 1.02; HR 1.00, 95% CI 0.97 to 1.03,
respectively) (Fig. 4; Additional file 1: Table S8). In
Fig. 2 Treatment receipt ratio (total treatments received out of total eligible) by comorbidity group including those without comorbidity and
those with one or more comorbidity. AMI patients presenting with the specified condition may have any of the other 6 comorbidities
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contrast, patients with heart failure and no other co-
morbidity had a 25% greater risk of mortality despite
receiving optimal care (HR 1.25, 95% CI 1.03 to 1.52),
and those with only diabetes, COPD, chronic renal
failure, cerebrovascular disease and peripheral vascular
disease showed no improvement in survival after re-
ceiving optimal care (Additional file 1: Table S9, Fig-
ure S1). In the complete case analysis, only in
patients with heart failure was there no difference in
survival despite receipt of optimal care (HR 1.01, 95%
CI 0.94 to 1.09) (Additional file 1: Table S10).
Long-term survival for AMI patients with diabetes
mellitus, peripheral vascular disease, chronic renal fail-
ure and COPD or asthma was higher for those who re-
ceived optimal care compared with those who did not
(63.6% vs 53.6%; 62.1% vs 52.4%, 61.8% vs 56.0%, 62.6%
vs 52.9%, respectively) (Fig. 5). For patients with chronic
heart failure and cerebrovascular disease, and in those
with two or more comorbidities, there was no difference
in long-term survival between those who did and did
not receive optimal care (58.2% vs 51.4%; 60.3% vs 51.0%
and 62.6% vs 52.2%, respectively) (Fig. 5).
The magnitude and direction of the estimates were upheld
in sensitivity analyses comparing the imputed data with a
complete case analysis, with the exception of AMI with
cerebrovascular disease and patients with two or more co-
morbidities (Additional file 1: Table S9, S11; Figure S2, S3).
Discussion
In this nationwide study of nearly 700,000 people hospita-
lised with AMI, we have shown that the co-existence of dia-
betes mellitus, COPD or asthma, chronic heart failure and
cerebrovascular disease is common and is inversely associ-
ated with receipt of optimal guideline-recommended care
for AMI. The most pronounced difference in care provision
was seen amongst those with chronic heart failure com-
pared to those without. Overall, the receipt of optimal AMI
care was associated with reduced mortality. However, in pa-
tients with chronic heart failure and cerebrovascular disease
or those with two or more comorbidities, there was no sig-
nificant improvement in survival despite receipt of optimal
guideline-indicated AMI care.
Whilst there have been substantial improvements in
long-term survival for patients with AMI, predominantly
owing to an increased uptake of an invasive coronary
strategy [20], the prognosis for patients with heart failure
remains poor [26]. In this study, the long-term survival
of patients with AMI was almost 50% lower if they had
concomitant heart failure. These disadvantaged out-
comes may relate to decreased provision or efficacy of
Fig. 3 Association of comorbidities with receipt of optimal AMI care. Missing data multiply imputed. Patients with each of the chronic conditions
may be subject to diagnosis of the 6 other chronic conditions. *Adjusted for GRACE risk, sex, year of diagnosis, smoking status, IMD score and all
seven chronic conditions; multiple imputation by chained equations was used to produce 10 imputed datasets to minimise potential bias due to
missing data. COPD, chronic obstructive pulmonary disease; IMD, index of multiple deprivation (continuous); Global Registry of Acute Coronary
Events (GRACE) risk score; patients were classified as ineligible if a treatment was recorded in MINAP as contraindicated, not indicated, or not
applicable; if the patient declined treatment; or if the patient was hospitalised prior to the guideline treatment recommendation
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therapy. In this study, we have shown that patients with
chronic heart failure and cerebrovascular disease and
those with two or more comorbidities had a 37%, 14%
and 17% reduced chance of receiving optimal care in
comparison to those without comorbidities. However,
when patients with chronic heart failure, cerebrovascular
disease or two or more comorbidities did receive optimal
guideline-indicated AMI care, there was no evidence of
a survival benefit compared with those who did not re-
ceive optimal guideline-indicated AMI care. There are
many possible reasons for the lack of survival benefit
seen amongst these comorbidity groups. In particular,
evidence-based care for AMI is largely determined by
randomised clinical trials that were optimised to focus
on single diseases and single disease pathways, and the
relative efficacy of the interventions in the presence of
comorbidity is not known. Additionally, the prognosis of
these AMI subgroups, in particular for patients with
concomitant heart failure, is poor and may lack revers-
ibility, and some of the current therapies may be poorly
tolerated or lack benefit [1]. Data demonstrating the effi-
cacy of novel therapies, such as sodium-glucose cotran-
sporter 2 (SGLT2) inhibitors, in patients with heart
failure and a reduced ejection fraction (even in a non-
diabetic population) offers some grounds for optimism
in this population [27]. In particular, our findings
highlight the importance of developing research into
new therapeutics which take into account the multimor-
bid nature of the majority of patients with AMI.
Our research identifies the overall low use of guideline-
indicated therapies, including P2Y12 inhibitors for which
the overall receipt of care was 39% and the use of invasive
coronary strategies which was 29%, 38% and 47% amongst
those with chronic heart failure and cerebrovascular dis-
ease and those with ≥ 2 comorbidities. We have previously
reported on the overall low provision of care in detail [21,
24] and note that there are several explanations why this
might be the case. The management of AMI is governed
by international guidelines which are frequently updated
[22, 28], and there is an underlying assumption that these
are implemented into healthcare. However, as well as time
lags associated with implementation, there are differences
between international guidelines and national guidelines
for the UK [29]—leading to inconsistency in implementa-
tion across the healthcare system. Moreover, the manage-
ment of AMI is multifaceted, and this is particularly the
case for people with comorbidities who may have compet-
ing healthcare needs, contraindications and differing prior-
ities. For patients with comorbidities (and those with
NSTEMI in particular, amongst whom comorbidity is
more common), the approach to clinical management is
heterogenous. Decisions regarding prescription or non-
Fig. 4 Association of receipt of optimal AMI care with long-term survival in the absence or presence of each comorbidity. Missing data multiply
imputed. Patients with each of the chronic conditions may be subject to diagnosis of the 6 other chronic conditions. *Adjusted for GRACE risk,
sex, year of diagnosis, smoking status, IMD score and all seven comorbidities; multiple imputation by chained equations was used to produce 10
imputed datasets to minimise potential bias due to missing data, and hazard ratios presented are pooled across all ten imputations. COPD,
chronic obstructive pulmonary disease; IMD, index of multiple deprivation (continuous); Global Registry of Acute Coronary Events (GRACE)
risk score
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prescription of evidence-based medications, or to proceed
to coronary angiography, are determined at the level of the
physician in a non-emergent setting, and informed by the
priorities and preferences of the patient. Finally, there is a
known treatment-risk paradox with regard to the provision
of invasive coronary procedures. Our previous work dem-
onstrated that fewer than half of a predominantly (> 80%)
high-risk NSTEMI population received invasive coronary
procedures [20]. It is likely that patients with two or more
comorbidities are amongst the highest-risk patients. The
levels of care provision identified in this study are consist-
ent with international comparisons, in which patients with
AMI and heart failure are less likely to undergo reperfusion
or be prescribed on aspirin on hospital discharge [30].
One strength of this study was the use of MINAP,
which is the largest nationwide single healthcare system
database of prospectively collected data on patients with
AMI, with robust mortality data provided through link-
age to the Office of National Statistics. Our analysis using
imputed data allowed a more complete analytical approach
in order to examine the effect of comorbidity states on
receipt of optimal care, and the impact of this interaction on
survival. To our knowledge, this is the first such analysis.
However, we recognise the limitations of our work. We were
reliant upon the accurate recording of data in MINAP.
Whilst case ascertainment in MINAP is high, not all cases of
NSTEMI in England and Wales are entered in the registry
[19]. Moreover, we have relied on the accurate recording of
comorbidities in MINAP and were limited to studying the
set of conditions specifically collected as part of a patients’
medical history. Patients may have had additional comorbidi-
ties that could have influenced their treatment that we were
unable to account for, and this may in part explain why the
overall provision of invasive coronary angiography in patients
without comorbidities appeared low (57%). We used a strict
definition of optimal care based on an “all or none” ap-
proach, which could misclassify some patients for which data
were missing. However, in addition to our multiple imput-
ation approach (to minimise potential bias caused by missing
data), we also conducted a sensitivity analyses using a cumu-
lative treatment score to capture the variation in treatment
provision, which showed consistent results. We did not have
Fig. 5 Survival graph of optimal AMI care vs suboptimal AMI care. *Adjusted for GRACE risk, sex, year of diagnosis, smoking status and IMD score
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data on post-AMI hospital admissions; therefore, we were
unable to account for competing events occurring within the
follow-up period. We were not able to quantify uptake of
cardiac rehabilitation, as only the presence of a referral to
cardiac rehabilitation is recorded within MINAP. Moreover,
our analyses were restricted to all-cause mortality; however,
in the context of multimorbidity, this may be a more clinic-
ally useful measure than cause-specific mortality [31].
There is a degree of urgency to improving care for pa-
tients with multimorbidity, as there is clear evidence that
population ageing and improved survival from acute illness
have led to a substantial increase in the burden of comor-
bidity in patients with cardiovascular disease over recent de-
cades [32]. There is a need for both increased recognition
of the adverse prognostic implications of multimorbidity,
but also a clear understanding of the clinical profiles of pa-
tients in whom current guideline-indicated therapy is less
effective. This will enable clinicians to more accurately
prognosticate, to inform shared decision-making and also
to target future medical intervention to this vulnerable
group.
Conclusions
In this large, nationwide cohort study, we have investi-
gated the association between comorbidities, receipt of
care and clinical outcomes for patients with AMI. We
showed that patients with heart failure, cerebrovascular
disease, diabetes mellitus and COPD or asthma were less
likely to receive guideline-recommended care. Whilst
overall, guideline-indicated care was associated with im-
provements in mortality, this study found no effect in
patients with heart failure or cerebrovascular disease.
These findings suggest that there is a need to improve
adherence to guideline-recommended therapy in AMI
patients with concomitant diabetes mellitus and COPD
or asthma who were less likely to receive optimal care—
but for whom prognosis could be improved if optimal
care was provided. Whilst questions around develop-
ment of future comorbidities following AMI remain un-
answered, our findings do suggest there may be a need
for the development of novel treatment pathways specif-
ically aimed at improving outcomes for AMI patients
with pre-existing heart failure or cerebrovascular disease.
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